0.4%), and dizziness (2% vs 2%). 3 DB placebo patients (1.1%) discontinued due to AEs during OL. There were no SAEs.
P-66 EFFICACY OF AN OLMESARTAN MEDOXOMIL-BASED TREATMENT ALGORITHYM FOR HYPERTENSION CONTROL IN PRACTICE-BASED SETTINGS
Introduction: Surveys preformed to assess blood pressure (BP) control have repeatedly demonstrated worldwide BP control rates of approximately 25%. In contrast, recent clinical trials have shown that forcedtitration treatment algorithms can help clinicians achieve diastolic BP goals in the vast majority of patients. Systolic BP goals, however, are much more difficult to achieve. In this study we sought to establish a treatment algorithm for a typical clinical setting designed to attain the increasingly accepted stringent BP control of Յ130/85 mm Hg in the majority of patients. The new long-acting angiotensin receptor blocker (ARB) olmesartan medoxomil was the base therapy and additional agents were permitted to achieve target BP.
Methods: This open-label, multicenter, forced-titration study enrolled 201 subjects at 17 clinical practice sites. Subjects were characteristic of hypertensive patients commonly seen in U.S. clinical practice. Mean age was 53 years; 65% were male; 74% were Caucasian; 16% were African-American; mean BP was 161.2/96.6 mm Hg. Following wash-out, all subjects received olmesartan medoxomil 20 mg; if target BP was not achieved at 4 weeks, olmesartan medoxomil was titrated to 40 mg. In step-wise manner, hydrochlorothiazide (HCTZ) 12.5 mg to 25 mg and amlodipine 5 mg to 10 mg were added sequentially beginning at 8 weeks and every 4 weeks thereafter if BP was not at goal.
Results: With this algorithm, olmesartan medoxomil monotherapy controlled DBP to Յ90 mm Hg in 80 % of subjects and SBP to Յ140 mm Hg in 61% of subjects. Using these BP targets, DBP control rates increased to 91%, 96%, 97%, and 97%, respectively, following the addition of HCTZ 12.5 to 25 mg and amlodipine 5 to 10 mg. SBP control rates increased to 78%, 85%, 92% and 94%, respectively, with the stepped algorithm. Overall, 92% of subjects attained the BP goal of Յ140 and Յ90 mm Hg with the olmesartan medoxomil-based regimen, and 82% attained the more stringent goal of Յ130 and Յ85 mm Hg.
Conclusions: We have demonstrated that when forced by a study protocol to follow a logical drug algorithm, doctors in a clinical setting achieved a BP goal of Յ130/85 mm Hg in more than 80% of subjects using an olmesartan medoxomil-based regimen. Aliskiren (SPP 100), an orally active renin inhibitor, has been shown to inhibit the production of angiotensin I and angiotensin II in healthy volunteers. In a pilot study, aliskiren decreased BP in hypertensive patients at daily doses of 75 and 150 mg.
In this multi-centre, double-blind, active comparator trial, the dosedependent effects of aliskiren were evaluated in 226 patients with mild to moderate hypertension. Parallel groups of randomized patients were assessed at the end of a washout period and again after a 4-week treatment period. aliskiren (37.5, 75, 150 or 300 mg) or of losartan 100 mg once daily. Daytime ambulatory systolic BP was defined as the primary variable of the study. As illustrated in the figure, a clear dose-response curve was observed for the decrease (mean ϩ/-SEM) in daytime ambulatory systolic BP. The mean (SD) change at the end of the 4-week treatment period was -1.3 (9.5) mmHg, -5.5 (10.6) mmHg, -8.5 (10.4) mmHg, -10.5 (10.7) mmHg, and -11.1 (13.4) mmHg for 37.5, 75, 150, and 300 mg aliskiren and 100mg losartan, respectively. Statistically significant lowering occurred with 75, 150 and 300 mg of aliskiren. The daytime ambulatory systolic BP responses to aliskiren doses of 150 and 300 mg were not significantly different from that of 100 mg losartan. Similar results were shown for daytime ambulatory diastolic BP and for night-time ambulatory systolic and diastolic BP. Aliskiren was well tolerated -there was no increase in the number of adverse events with increasing doses of aliskiren, and the safety profile of aliskiren was similar to that of losartan.
The results of this dose-ranging study confirm a dose-dependent reduction in BP with aliskiren in mild to moderate hypertension. Additional exploratory studies testing the efficacy and safety of this new renin inhibitor in patients with renal disease and congestive heart failure are currently underway.
Key Words: Renin Inhibitor, Oral Administration, Hypertension Introduction: This double-blind, randomized, multicenter study was conducted to compare the efficacy of the newest angiotensin receptor blocker (ARB), olmesartan medoxomil, with one of the most commonly prescribed antihypertensive agents, amlodipine, in subjects with mild-tomoderate hypertension. Olmesartan medoxomil is a new, long-acting, once-daily ARB that has been shown in a previous study to result in statistically superior reductions in blood pressure (BP) as compared with three other ARBs: losartan, valsartan, and irbesartan.
P-68 THE ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL COMPARED WITH AMLODIPINE FOR MILD-TO-MODERATE HYPERTENSION
Methods: Following a 4-week placebo run-in period, subjects were randomized to 8 weeks of therapy with placebo (nϭ66), or the recommended starting doses of amlodipine 5 mg (nϭ186) or olmesartan medoxomil 20 mg (nϭ188). The primary efficacy variable was the change from baseline in mean 24-hour diastolic BP as determined by ambulatory BP monitoring at Week 8. Entry criteria included seated cuff diastolic BP 100-115 mm Hg and daytime, ambulatory diastolic BP Ն90 mm Hg. There were no statistically significant differences between groups at baseline. Mean baseline 24-hour ambulatory BP in the placebo, amlodipine and olmesartan medoxomil groups was 154/96, 154/95, and 154/96 mm Hg, respectively.
Results: Both active treatments reduced BP at all measures to a significantly greater degree than did placebo; there were no statistically significant differences in BP efficacy between amlodipine and olmesartan medoxomil on any measure. Ambulatory systolic/diastolic BP was reduced by 2.3/1.4 on placebo, 12.3/7.0 on amlodipine, and 12.2/7.7 on olmesartan medoxomil (PϽ0.001 amlodipine and olmesartan medoxomil vs placebo). Similar findings were reported for cuff BP measurements. Both agents were equally well-tolerated. The only notable differences in adverse events were a significantly higher incidence of nausea (2.7%) with amlodipine as compared with olmesartan medoxomil (0%) or placebo (0%) (Pϭ0.039), and a higher, but not statistically significant, incidence of edema with amlodipine (9.1%) compared with olmesartan medoxomil and placebo (4.3%, and 4.5%, respectively.
Conclusions: Olmesartan medoxomil is safe and similarly effective to amlodipine in subjects with mild-to-moderate hypertension, resulting in equivalent reductions in both cuff and ambulatory systolic and diastolic BP.
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P-69 ATORVASTATIN ASSOCIATED TO VALSARTAN DOES NOT IMPROVE BLOOD PRESSURE CONTROL OR PROTEINURIA EXCRETION IN PATIENTS WITH DIABETIC NEPHROPATHY
Jesus Arteaga, Maria Sorbet, Emma Anda, Manuel Asiron. Nephrology, Hospital de Navarra, Pamplona, Spain. In recent years several papers have been published (1) showing that the use of statins with some antihypertensive drugs could improve the blood pressure control and could have some synergetic effect(2).
Our proposal had a double Objective: To analyse if atorvastatin is able to reduce blood pressure and if it is able to decrease proteinuria in a group of patients with diabetic nephropathy, hypercholesterolemia and hypertension treated with one angiotensin receptor blocker. We included 6 patients (3M,3F), aged (58-71)in treatment with valsartan 160 mg/day as only antihypertensive drug.
The study was an open, secuential design with each period lasting 3 months. Period A: valsartan 160 mg/day. Period B: valsartan 160mg/day and atorvastatin 10 mg/day. Period C: valsatan 160 mg/day. We can detect significant differences in total cholesterol and LDL-cholesterol between periods with and without atorvastatin (pϽ0,001). There were no significant differences in blood pressure control, serum creatinine or proteinuria in 24 hours.
In conclusion, we can not confirm that atorvastatin treatment modifies systolic or diastolic pressure or has some influence in the progression of diabetic nephropathy in patients previously treated with valsartan.
(1). 
